Evaluate of Tolterodine for lower urinary tract syndrome after prostate Brachytherapy

Evaluate of Tolterodine for lower urinary tract syndrome after prostate Brachytherapy - Evaluate and safety of Tolterodine for lower urinary tract syndrome after prostate Brachytherapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004843

Enrollment

Registered

2011-01-20

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Urief tab(4mg b.i.d) 12week Detrusitol cap(4mg, daily) 8week

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: -40<or=age80 -Patient to whom alfa-1-blocker is administered after treatment for prostate brachytherapy -OABSS(Q3)>or=2, OABSS(total)>or=3

Exclusion criteria

Exclusion criteria: 1. PVR>or=100cc 2. Patient with urinary tract infection 3. Patient of anti-cholinergic medicine administration taboo a. Patient with urinary retention b. Patient whose pylorus or duodenum or ileum are obstructed, or who has paralytic ileus c. Patient whose digestive organ movement or tention are decreased d. Patient with narrow-angle glaucoma e. Patient with myasthenia gravis f. Patient with severe heart disease g. Patient with sevre hepatic dysfunction (Child-Pugh classification C) h. Patient with hypersentivity for anti-cholinergic medicine

Design outcomes

Primary

Measure	Time frame
To verify change rate of Overactive Bladder symptom score(OABSS) after 8week	—

Countries

Japan

Contacts

Public ContactHirohiko Nagata

Keio University School of Medicine Department of Urology

03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026